Printer Friendly

PAREXEL APPOINTS SENIOR EUROPEAN EXECUTIVE

 WALTHAM, Mass., July 9 /PRNewswire/ -- PAREXEL International Corporation (PAREXEL) today announced that Prof. Dr. med. Holger Franke has joined the company's European operations as general manager, Central Region, based in Berlin. In this position, Franke will be responsible for the general management of PAREXEL's Central European operations, and will report to the president of European operations.
 Franke brings to PAREXEL over 20 years of experience in the fields of pharmaceutical product development, Phases I - IV, and clinical pharmacology. He was president of the Clinical Research Foundation, a German-based independent pharmaceutical research organization formerly owned by Boehringer Ingelheim. Prior to that appointment, Franke held several senior management positions in the research function of Boehringer Ingelheim.
 "Prof. Franke brings to our European operations not only a wealth of experience in pharmaceutical development, but a hands-on understanding of the business, management, and strategic aspects of operating an independent pharmaceutical research organization in Europe," stated Josef von Rickenbach, PAREXEL's chairman, CEO. "This experience and knowledge will be essential as we expand our European operations."
 A German citizen, Franke studied medicine at the University of Kiel and the University of Berlin, and received his Doctor of Medicine in 1969.
 PAREXEL International Corporation is one of the world's largest independent pharmaceutical research organizations. The company offers clinical trials management, regulatory affairs consulting, data management, biostatistical and other services to the pharmaceutical, biotechnology, medical device and diagnostics industries.
 PAREXEL's European operations, with over 300 employees located in Paris, London, Berlin and Frankfurt, provide Phase I through Phase IV clinical drug research and new drug registration services in support of product filings in Europe.
 -0- 7/9/93
 /CONTACT: Josef von Rickenbach, chairman and chief executive officer of PAREXEL International Corporation, 617-487-9900, or Anthony J. Russo, Ph.D., or Susan Noonan of Noonan/Russo Communications, Inc., 212-979-9180, for PAREXEL/


CO: PAREXEL International Corporation ST: Massachusetts IN: MTC SU: PER

SM-OS -- NY012 -- 9816 07/09/93 09:56 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 9, 1993
Words:320
Previous Article:ARGOSY GAMING SUBSIDIARY SUBMITS PROPOSAL AND NAMES BOARD OF DIRECTORS
Next Article:FAIRCHILD ANNOUNCES MANAGEMENT CHANGE
Topics:


Related Articles
PAREXEL NAMES PRESIDENT, EUROPEAN OPERATIONS
PAREXEL Acquires CRO in Israel
PAREXEL Reports Fourth Quarter and Fiscal 1998 Financial Results
PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors.
PAREXEL Enhances Study Start-Up and Recruitment Capabilities With Appointment of Dr. Lars-Olof Eriksson, Formerly With Merck.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters